Purdue announced that Butrans (buprenorphine) Transdermal System will be available for ordering the week of January 10, 2011. Butrans is approved for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.
Butrans is a Schedule III controlled substance. It will be available in 5microgram/hour, 10microgram/hour, and 20microgram/hour dosage strength patches that release medication continuously for seven days.
For more information call (888) 726-7535 or visit www.butrans.com.